15.12.2010 • News

Hadasit Bio-Holdings is an Investment Interest for Sanofi-Aventis

French drugmaker Sanofi-Aventis is in talks to invest in Hadasit Bio-Holdings, the Israeli biotech holding company said on Tuesday.

Hadasit said the potential investment would be in its KHAR Medical unit, but that no deal had yet been reached. It noted that it was responding to a report in Israel's Calcalist newspaper.

Hadasit, the technology transfer company of Jerusalem's Hadassah University Hospital, said the deal could be thwarted by the disclosure of the talks in the newspaper.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Interview

Driving Transformation
Interconnected Global Chemicals Logistics

Driving Transformation

DP World is reshaping global chemical supply chains. Christene Smith of CHEManager interviews Markus Kanis, Global SVP Chemicals, on the company’s roadmap, new technologies, and the evolving demands of global trade.

most read